Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > ARCHIVE
ARCHIVE
- Pfizer Obtains Approval for Generics of 14 APIs
August 1, 2011
- US FDA Announces Draft Guidance for Simultaneous Development of Therapeutics and Companion Diagnostic Devices
August 1, 2011
- Daiichi Sankyo Espha to Deal with Both Long-listed Products, Generics
August 1, 2011
- Biosimilars Optimize Healthcare Costs: JSGM Seminar
August 1, 2011
- AZ, NCC Announce Comprehensive Agreement for Development of Anticancer Drugs
August 1, 2011
- Eisai Launches Halaven in Japan; Product to Be Detailed by All 1,400 MRs
August 1, 2011
- Volume-based Generics Market Share Up to 23.0% in FY 2010: JGA
August 1, 2011
- Shionogi Starts 4th PIII Study of the HIV Treatment S-349572
August 1, 2011
- Daiichi Sankyo Launches Lixiana for Prevention of VTE
August 1, 2011
- JGA Compiles Model Corporate Ethics Standards
August 1, 2011
- Takeda to Beef Up Its OTC Drugs Business in Asia
August 1, 2011
- RaQualia Listed on JASDAQ; Aims to Raise ¥6.3 Bil.
August 1, 2011
- MTPC Ordered to Stop Operations for 10 Days at Subsidiary Plant
August 1, 2011
- Japan Federation of Non-prescription Medicines Industry Set Up by 5 Organizations
August 1, 2011
- Astellas to Drive Business in Emerging Markets Based on GCL Strategy: Vice Deputy Chairman Ishii
August 1, 2011
- Council Starts Discussing How to Realize Proposed Social Security/Tax Reform Plan
August 1, 2011
- 3 Vaccines Judged to Be Safe “at Present Time”: PAFSC Study Groups
August 1, 2011
- Chugai: Operating Profits Up 27% in 1st Half
August 1, 2011
- EMA Asks Takeda to Revise Package Inserts for Pioglitazone Medicines Due to Risk of Bladder Cancer
August 1, 2011
- PAFSC Subcommittee Recommends Classification of 4 Crude Drugs as Class 2 OTC Drugs
August 1, 2011
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…